Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt

Abstract

Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients. © 2007 The Authors.